ArticleDiscover oncology2026
Comprehensive analysis of disulfidptosis-related genes identifies clinically actionable prognostic biomarkers in cholangiocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeCholangiocarcinoma (CCA), a malignancy of the hepatobiliary system, lacks predictive biomarkers due to the scarcity of publicly available datasets. Disulfidptosis, a recently identified form of regulated cell death, is triggered by disulfide accumulation in SLC7A11-high tumor cells under glucose deprivation. Its role in CCA, however, remains unexplored.
methodsWe systematically evaluated the transcriptional and mutational profiles of disulfidptosis-regulating genes (DRGs) in CCA. Based on their expression, distinct disulfidptosis clusters (CDR clusters) were defined. Differentially expressed genes (DEGs) derived from these clusters were used to classify the samples into Gene Cluster A and Gene Cluster B. A subsequent prognostic risk model was then developed. Clinical characteristics, immune cell infiltration (assessed via Immune Score and ESTIMATE Score), and drug sensitivities were compared between high- and low-risk groups.
resultsMost disulfidptosis-regulating genes exhibited significant differential expression and prognostic value in CCA. DEG analysis defined Gene Clusters A/B. Four key genes—RTN4RL1, SLC13A1, FOSL1, and COX6B2—were identified to construct the prognostic model. The high-risk group exhibited significantly poorer overall survival in both the training cohort (n = 262; AUC 1–3 years: 0.796–0.819) and an independent external validation cohort (n = 30; AUC 1–3 years: 0.804–0.868). Multivariate analysis confirmed the risk score as an independent prognostic factor. The high-risk group demonstrated significantly elevated Immune Scores and ESTIMATE Scores. Drug sensitivity analysis revealed differential responses between risk groups, identifying potential therapeutic agents for CCA. qPCR validation in independent CCA patient specimens confirmed significant upregulation of high-risk genes (FOSL1, COX6B2) and downregulation of low-risk genes (RTN4RL1, SLC13A1) in tumor tissues, corroborating our bioinformatic findings.
conclusionThis represents the first systematic exploration of the prognostic associations and tumor microenvironment implications of disulfidptosis-related genes (DRGs) in CCA. Our findings elucidate the role of disulfidptosis, reveal its association with the tumor immune microenvironment, and our in silico drug sensitivity analysis generates hypotheses for potential therapeutic strategies that may be tested in future preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.